Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Latest news

2/7/2024 RNC Pharma: Share of US Veterinary Manufacturers in Retail Market Drops 6%

In 2023, 35.4 billion rubles’ worth of veterinary drugs were sold on the Russian retail market (retail prices, VAT included), up 22.5% from 2022, which is record-worthy. In physical terms, 235 million minimum dosage units (MDU) were sold, up 13%. The difference in growth rates can be easily explained by the inflation rate. Interestingly, the online market continued to actively develop—online sales went up 2.2 times in MDUs, while offline sales grew by only 5%.

2/6/2024 RNC Pharma: Most Expensive Glucose Meters Sold in North Caucasus, Most Expensive Test Strips in Far East

In 2023, 1.38 million glucose meters and around 657.3 million glucose test strips were sold on the Russian retail market, down 0.3% and 3.5% from 2022, respectively.

2/2/2024 RNC Pharma: Russian Consumers of Nebulizers Prefer Marketplaces to Pharmacies, Except in Far East

In 2023, 4.9 billion rubles’ worth of nebulizers were sold on the Russian retail market (retail prices, VAT included), up only 0.5% from 2022. At the same time, the sales in physical terms went up by as much as 9.6%. Online sales alone contributed to the total growth rates, with its 40.4% in monetary terms and 67.6% in physical terms.

2/1/2024 Pharmaceutical Drug Production in Russia in 2023

In 2023, Russian manufacturers produced 716.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 7.2% from 2022. In physical terms, it was 4.09 billion packages, down 2% from 2022.

1/31/2024 RNC Pharma: More Than 6M Blood Pressure Monitors Sold in Russia in 2023, Up 29%

In 2023, around 6.03 million of all types of blood pressure monitors worth 11.87 billion rubles (retail prices, VAT included) were sold in the offline and online retail market in Russia.

All news [394]

Our competences

RNC Pharma is focused on providing information about development trends of Russian pharmaceutical market infrastructure component. Our experts also provide services on strategic marketing, such as forecasting, business planning, etc.